The content below is specific to Novartis Canada. To see all Novartis content, please visit the Novartis Global site.
Header
News Archive
Showing 30 results
May 2024
-
Media ReleaseNOVARTIS CANADA AND CLARIUS MOBILE HEALTH CHALLENGE STANDARD OF CARE FOR PSORIATIC ARTHRITIS WITH NEW PARTNERSHIPPsoriatic arthritis is a chronic, autoimmune disease form of arthritis that causes joint inflammation (swelling, pain, stiffness) and occurs with skin condition psoriasis. It can also affect the…
-
Media ReleaseHealth Canada approves Cosentyx®, a biologic therapy, for the treatment of adults with moderate to severe Hidradenitis Suppurativa (HS)Approval is based on the two largest Phase III trials conducted in HS – SUNSHINE and SUNRISE – demonstrating the safety and efficacy of Cosentyx® in HS1HS is a chronic, immunological, inflammatory…
March 2024
-
Media ReleaseHealth Canada grants approval of the Eye-Tracking Neurological Assessment for Multiple Sclerosis (ETNA™-MS) for use in tracking disease progression in people living with MSMore than 90,000 Canadians—or one in 400 people across Canada—live with multiple sclerosis (MS),1 a neurodegenerative, chronic condition that affects the central nervous system.2Despite decades…
-
Media ReleaseNovartis Canada’s statement on CADTH draft recommendations for LEQVIO® (inclisiran)Montréal, QC, March 21, 2024 – Novartis Pharmaceuticals Canada Inc. (Novartis Canada) is deeply disappointed with the draft recommendations of the Canadian Drug Expert Committee (CDEC) issued by…
September 2022
-
Media ReleaseNovartis and the pan-Canadian Pharmaceutical Alliance (pCPA) conclude negotiations for Luxturna®, a gene therapy for previously untreatable inherited vision loss¹Luxturna® (voretigene neparvovec) is a one-time gene therapy that provides healthy copies of the RPE65 gene for retinal cells that are lacking the normally functioning gene1 Dorval, QC, September…
-
Media ReleaseHealth Canada approves PLUVICTO™ as first targeted radioligand therapy for progressive PSMA positive metastatic castration-resistant prostate cancerNovel mechanism of action of PLUVICTO™ binds to target PSMA-positive cancer cells, delivering radiation treatment directly to those cells and nearby cells1 Prostate cancer is the most diagnosed…